Drug
Osilodrostat clinical trials
Also written LCI699.
- studies test it
- 17
- open now
- 6
- in phase 3
- 2
- first study started
- 2008
Keep track of what changes. Save the Osilodrostat studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Studies by the year they started
17 studies that test it; most in 2026 (4)
| Year | Studies |
|---|---|
| 2008 | 3 |
| 2009 | 1 |
| 2011 | 1 |
| 2014 | 1 |
| 2015 | 3 |
| 2016 | 1 |
| 2018 | 1 |
| 2021 | 1 |
| 2025 | 1 |
| 2026 | 4 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 2
- Phase 2
- 9
- Phase 3
- 2
- Phase 4
- 4
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 13 · Other 4
Novartis Pharmaceuticals (7) · RECORDATI GROUP (3) · Novartis (3) · University of Basrah (1) · Johns Hopkins University (1) · Mayo Clinic (1) · Laikο General Hospital, Athens (1)
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses Osilodrostat is read from its arms, and is right about nine times in ten.
Testing it · 17
- Isturisa Treatment in Mild Autonomous Cortisol Secretion( MACS)RecruitingPhase 4Johns Hopkins UniversityNCT07247058Written as Osilodrostat (Isturisa)
- Combination Osilodrostat and Cabergoline in Cushing's DiseaseEnrolling by invitationPhase 4University of BasrahNCT07603466Written as osilodrostat
- Pharmacokinetic (PK), Pharmacodynamic (PD) and Tolerability of Osilodrostat in Pediatric Patients With Cushing's SyndromeRecruitingPhase 2RECORDATI GROUPNCT03708900Written as LCI699
- Impact of 1 mg Osilodrostat Therapy on Mild Autonomous Cortisol Secretion (MACS)RecruitingPhase 2Mayo ClinicNCT07104812Written as Osilodrostat 1 MG
- Osilodrostat in Patients With Hypertension Caused by Hypercortisolaemia Due to Cushing's SyndromeNot yet recruitingPhase 4RECORDATI GROUPNCT07247162Written as Osilodrostat
- Metyrapone Versus Osilodrostat in Patients With Metabolic Autonomous Cortisol Secretion (MACS)RecruitingPhase 4Laikο General Hospital, AthensNCT07268222Written as Osilodrostat 1 MG
- Roll-over Study in Patients With Endogenous Cushing's Syndrome for LCI699CompletedPhase 2RECORDATI GROUPNCT03606408Written as osilodrostat
- Efficacy and Safety Evaluation of Osilodrostat in Cushing's DiseaseCompletedPhase 3Novartis PharmaceuticalsNCT02697734Written as osilodrostat
- A Study to Evaluate Efficacy and Safety of LCI699 in Participants With Essential HypertensionCompletedPhase 2Novartis PharmaceuticalsNCT00758524Written as LCI699
- A Study to Evaluate the Efficacy and Safety of LCI699 Compared to Placebo in Participants With Resistant HypertensionCompletedPhase 2NovartisNCT00817635Written as LCI699
- A Study to Evaluate the Effects of LCI699 on Cortisol in Participants With HypertensionCompletedPhase 2NovartisNCT00817414Written as LCI699
- Safety and Efficacy of LCI699 in Cushing's Disease PatientsCompletedPhase 2Novartis PharmaceuticalsNCT01331239Written as LCI699
- Safety and Efficacy of LCI699 for the Treatment of Patients With Cushing's DiseaseCompletedPhase 3Novartis PharmaceuticalsNCT02180217Written as osilodrostat
- A Phase 1 Study of Osilodrostat (LCI699) in Healthy Volunteers and Subjects With Impaired Hepatic FunctionCompletedPhase 1Novartis PharmaceuticalsNCT02372084Written as osilodrostat
- A Phase I Study of Osilodrostat (LCI699) in Healthy Volunteers and Subjects With Impaired Renal FunctionCompletedPhase 1Novartis PharmaceuticalsNCT02399202Written as osilodrostat
- Study of Efficacy and Safety of Osilodrostat in Cushing's SyndromeCompletedPhase 2Novartis PharmaceuticalsNCT02468193Written as Osilodrostat
- Proof-of-concept for the Aldosterone Synthase Inhibitor LCI699 in Patients With Primary HyperaldosteronismCompletedPhase 2NovartisNCT00732771Written as LCI699
Codes
What other systems call Osilodrostat · ClinicalTrials.gg INT005732
- MeSH (NLM) C553306OsilodrostatConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) 5YL4IQ1078OSILODROSTATConfirmed FDA, NLM, Wikidata
- RxNorm 2286252Confirmed FDA, Wikidata
- Wikidata Q27088216osilodrostatConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C131535OsilodrostatOne source FDA
- DrugBank DB11837One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C553306 | Osilodrostat | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | 5YL4IQ1078 | OSILODROSTAT | Confirmed FDA, NLM, Wikidata |
| RxNorm | 2286252 | — | Confirmed FDA, Wikidata |
| Wikidata | Q27088216 | osilodrostat | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C131535 | Osilodrostat | One source FDA |
| DrugBank | DB11837 | — | One source Wikidata |
Also registered as osilodrostat phosphate (UNII Y6581YAW9V · RxNorm 2286253).
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.